On linezolid efficacy and tolerability

De Lorenzo S., Centis R., D'Ambrosio L., Sotgiu G., Migliori G.B.

Source: Eur Respir J 2012; 39: 770-772
Journal Issue: March

Full text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
De Lorenzo S., Centis R., D'Ambrosio L., Sotgiu G., Migliori G.B.. On linezolid efficacy and tolerability. Eur Respir J 2012; 39: 770-772

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China
Source: Eur Respir J 2015; 45: 161-170
Year: 2015



Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China
Source: Eur Respir J 2016; 47:1591-1592
Year: 2016


Efficacy and safety of meropenem–clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB
Source: Eur Respir J 2013; 41: 1386-1392
Year: 2013



Linezolid: safety and efficacy monitoring
Source: Eur Respir J 2012; 39: 1276-1277
Year: 2012


Linezolid: safety and efficacy monitoring
Source: Eur Respir J 2012; 39: 1275-1276
Year: 2012


Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis
Source: Eur Respir J 2011; 38: 730-733
Year: 2011


A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis
Source: Eur Respir J 2009; 33: 387-393
Year: 2009



Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis
Source: Eur Respir J , 49 (3) 1601612; DOI: 10.1183/13993003.01612-2016
Year: 2017


Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis
Source: Eur Respir J 2012; 40: 1430-1442
Year: 2012



Safety, tolerability and efficacy of linezolid for the treatment of M/XDR-TB: A systematic review and meta-analysis
Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Year: 2011


Efficacy and tolerability of linezolid in multidrug-resistant tuberculosis (MDR/XDR-TB)
Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis
Year: 2008

Efficacy and safety of Linezolid in pneumonias
Source: Eur Respir J 2002; 20: Suppl. 38, 420s
Year: 2002

Efficacy, safety and tolerability of 3 day azithromycin versus 10-day amoxillin/clavulanic acid in the treatment of children with pneumonia
Source: Eur Respir J 2003; 22: Suppl. 45, 143s
Year: 2003

Efficacy and tolerability of voriconazole in the treatment of pulmonary aspergillosis
Source: Eur Respir J 2007; 30: Suppl. 51, 301s
Year: 2007

Efficacy and safety of chemotherapy regimens containing fluoroquinolones in pediatric TB
Source: Virtual Congress 2021 – Epidemiology and burden of tuberculosis and other lung diseases
Year: 2021


Efficacy and safety of levamisole as an immunomodulator in the treatment of drug resistant tuberculosis
Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II
Year: 2019


Clinical efficacy and safety of clarithromycin in the treatment of multi-drug resistant tuberculosis
Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance
Year: 2009


Evaluation of the efficacy and safety of levofloxacin in the treatment of resistant pulmonary tuberculosis; a clinical trial
Source: Eur Respir J 2002; 20: Suppl. 38, 546s
Year: 2002

The efficacy, safety and tolerability of the short 12-month pre-XDR-TB regimen regimen in Ukraine at the expense of using intravenous administration of anti-tuberculosis drugs during intensive phase
Source: International Congress 2017 – Paediatric TB: MDRTB (II)
Year: 2017

Efficacy and tolerability of nintedanib switched from pirfenidone for IPF patients
Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia
Year: 2019